Antiplatelet combo benefits post-CABG ‘durable for five years’
Chinese researchers report five-year outcomes in a trial comparing dual and single antiplatelet therapies
Five-year follow-up of a trial comparing dual and single antiplatelet therapies after elective coronary artery bypass graft surgery shows benefits in patients on the dual regimen persist, researchers report.
The results of the extension trial showed a 36-37% reduced incidence of a combination of major adverse cardiovascular events (MACE) in patients who used both ticagrelor and aspirin after their coronary artery bypass graft (CABG) procedure compared with others who used only one of the two therapies.
